Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade C 11.47 0.17% 0.02
IMMU closed up 0.17 percent on Friday, September 22, 2017, on 71 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical IMMU trend table...

Date Alert Name Type % Chg
Sep 22 NR7 Range Contraction 0.00%
Sep 22 Narrow Range Bar Range Contraction 0.00%
Sep 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Sep 18 NR7 Range Contraction 1.87%
Sep 18 Narrow Range Bar Range Contraction 1.87%

Older signals for IMMU ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.96
52 Week Low 2.02
Average Volume 2,603,682
200-Day Moving Average 6.9102
50-Day Moving Average 9.8607
20-Day Moving Average 11.7478
10-Day Moving Average 11.6565
Average True Range 0.602
ADX 25.91
+DI 23.25
-DI: 20.76
Chandelier Exit (Long, 3 ATRs) 11.154
Chandelier Exit (Short, 3 ATRs) 10.936
Upper Bollinger Band 12.7401
Lower Bollinger Band 10.7555
Percent B (%b) 0.36
Bandwidth 0.168934
MACD Line 0.4779
MACD Signal Line 0.6507
MACD Histogram -0.1728